FinTechFunding

Noxopharm: Announces novel mRNA “vaccine enhancer” product

Noxopharm Announces novel mRNA “vaccine enhancer” product

  • Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation
  • The company says it has selected a lead candidate for further development, and the product — dubbed SOF-VAC — will be part of its Sofra preclinical platform
  • NOX says SOF-VAC is the smallest known molecule of its type to have demonstrated “strong activity” against inflammation
  • The company is developing the product in partnership with the Hudson Institute of Medical Research
  • Shares in the company are up 3.16 per cent to 9.8 cents at midday AEDT
Previous article
Raisin: Announces €60 million funding
Next article
eToro: Announces major charting upgrade in partnership with TradingView
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

SWIFT Strengthens Blockchain-Based Shared Ledger for Real Transactions This Year

The financial messaging service aims to integrate blockchain technology in operations.Highlights: SWIFT plans to launch a blockchain-based shared...
FinTech

Nium Launches Dual-Network Stablecoin Card Issuance Platform

New platform aims to streamline stablecoin card issuance and enhance user experience.Highlights: Nium unveils a new platform for...
FinTech

Wise Launches UK Current Accounts, Expanding Financial Services

The new accounts aim to simplify banking for UK customers.Highlights: Wise introduces current accounts to UK market.The new...
FinTech

Lloyds Bank Strengthens Research on AI Impact in Software Engineering

The collaboration aims to explore the future of technology in banking.Highlights: Lloyds Bank partners with the University of...